Tag Archives: SAB Bio

Lilly’s Ph3 ATTAIN-MAINTAIN Results; Orforglipron Filed; Novo Files Cagrisema and Receives FDA Warning Letter; Merck to Receive CNPV; SAB BIO Pivotal Ph2b T1DM Trial; Sagimet Enters Agreement for Resmetirom

A series of cardiometabolic-related news items has been observed from Lilly, Novo Nordisk, Merck, SAB Biotherapeutics, and Sagimet Biosciences. Below, FENIX provides highlights and insights for the respective news items, including what Sagimet could be thinking vs. Madrigal.

This content is for Read Less members only.

Already a member? Log in here

Medtronic Launches Instinct CGM; SAB BIO Initiates Pivotal Ph2b T1DM Study; Lilly Terminates Ph2 Bimagrumab Study; Glooko Acquires Monarch Medical

A series of cardiometabolic-related news items has been observed from Medtronic, SAB BIO, Lilly, and Glooko. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Biomea Q4 ‘24 Earnings; Gubra Ph1 GUBamy Trial Updates; Sernova Ph1/2 Cell Pouch Study Updates; Updated SAB Q4 ’24 Earnings

A series of cardiometabolic-related news items has been observed from Biomea Fusion, Gubra, Sernova Biotherapeutics, and SAB BIO. Below, FENIX provides highlights and insights for the respective news items, including an updated topic from yesterday’s blast.

This content is for Read Less members only.

Already a member? Log in here

Novo, Lilly, and AZ Data at ACC 2025; Vertex T1DM Updates; Palatin Ph2 Obesity Results; Noom Integrates with LillyDirect; SAB Q4 ‘24 Earnings

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Lilly, AstraZeneca, Vertex Pharmaceuticals, Palatin Technologies, Noom, and SAB BIO. Additionally, FENIX will cover Biomea Fusion’s FY 2024 earnings in tomorrow’s blast. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here